

Citations

1. BHMA. Cascara bark. In: Bradley P, ed. British Herbal Compendium. 1 vol. Bournemouth, UK: British Herbal Medical Association; 1992.
2. McGuffin M, Hobbs C, Upton R, Goldberg A. American Herbal Products Association's Botanical Safety Handbook. Boca Raton, Fla: CRC Press; 1997.
3. Blumenthal M, Busse W, Goldberg A et al. The Complete German Commission E Monographs. Austin, Texas: American Botanical Council: Integrative Medicine Communications; 1998.
4. WHO. Cortex rhamni purshianae. WHO Monographs on Selected Medicinal Plants. 2 vol. Geneva: World Health Organization; 2002:259-268.
5. ESCOP. Rhamni purshiani cortex. ESCOP Monographs: The Scientific Foundation for Herbal Medicinal Products. 2nd ed. Exeter, UK: European Scientific Cooperative on Phytotherapy and Thieme; 2003:413-418.
6. Izzo AA, Gaginella TS, Mascolo N, Capasso F. Recent findings on the mode of action of laxatives: the role of platelet activating factor and nitric oxide. Trends Pharmacol Sci 1998;19:403-406.
7. Ishii Y, Tanizawa H, Takino Y. Studies of aloe. IV. Mechanism of cathartic effect. (3). Biol Pharm Bull 1994;17:495-497.
8. Izzo AA, Sautebin L, Rombola L, Capasso F. The role of constitutive and inducible nitric oxide synthase in senna- and cascara-induced diarrhoea in the rat. Eur J Pharmacol 1997;323:93-97.
9. Capasso F, Mascolo N, Autore G, Duraccio MR. Effect of indomethacin on aloin and 1,8 dioxanthraquinone-induced production of prostaglandins in rat isolated colon. Prostaglandins 1983;26:557-562.
10. Ishii Y, Tanizawa H, Takino Y. Studies of aloe. III. Mechanism of cathartic effect. (2). Chem Pharm Bull (Tokyo) 1990;38:197-200.
11. Ishii Y, Tanizawa H, Takino Y. Studies of aloe. V. Mechanism of cathartic effect. (4). Biol Pharm Bull 1994;17:651-653.
12. Zhang L, Lau YK, Xi L et al. Tyrosine kinase inhibitors, emodin and its derivative repress HER-2/neu-induced cellular transformation and metastasis-associated properties. Oncogene 1998;16:2855-2863.
13. Kumar A, Dhawan S, Aggarwal BB. Emodin (3-methyl-1,6,8-trihydroxyanthraquinone) inhibits TNF-induced NF- κ B activation, I κ B degradation, and expression of cell surface adhesion proteins in human vascular endothelial cells. Oncogene 1998;17:913-918.
14. Garg AK, Buchholz TA, Aggarwal BB. Chemosensitization and radiosensitization of tumors by plant polyphenols. Antioxid Redox Signal 2005;7:1630-1647.
15. Stockley I. Stockley's Drug Interactions. 6th ed. London: Pharmaceutical Press; 2002.
16. Leng-Peschlow E. Senna and its rational use. Pharmacology 1992;44 Suppl 1:1-52.
17. Zhou S, Gao Y, Jiang W et al. Interactions of herbs with cytochrome P450. Drug Metab Rev 2003;35:35-98.
18. Mueller SO, Stopper H, Dekant W. Biotransformation of the anthraquinones emodin and chrysophanol by cytochrome P450 enzymes: bioactivation to genotoxic metabolites. Drug Metab Dispos 1998;26:540-546.
19. Sun M, Sakakibara H, Ashida H et al. Cytochrome P4501A1-inhibitory action of antimutagenic anthraquinones in medicinal plants and the structure-activity relationship. Biosci Biotechnol Biochem 2000;64:1373-1378.
20. Wang HW, Chen TL, Yang PC, Ueng TH. Induction of cytochromes P450 1A1 and 1B1 by emodin in human lung adenocarcinoma cell line CL5. Drug Metab Dispos 2001;29:1229-1235.
21. Lin S-Y, Yang J-H, Hsia T-C et al. Effect of inhibition of aloe-emodin on N-acetyltransferase activity and gene expression in human malignant melanoma cells (A375.S2). Melanoma Res 2005;15:489-494.
22. Duvoix A, Delhalle S, Blasius R et al. Effect of chemopreventive agents on glutathione S-transferase P1-1 gene expression mechanisms via activating protein 1 and nuclear factor kappa B inhibition. Biochem Pharmacol 2004;68:1101-1111.
23. Li H-L, Chen H-L, Li H et al. Regulatory effects of emodin on NF- κ B activation and inflammatory cytokine expression in RAW 264.7 macrophages. Int J Mol Med 2005;16:41-47.
24. Zhang L, Chang CJ, Bacus SS, Hung MC. Suppressed transformation and induced differentiation of HER-2/neu-overexpressing breast cancer cells by emodin. Cancer Res 1995;55:3890-3896.
25. Zhang L, Hung MC. Sensitization of HER-2/neu-overexpressing non-small cell lung cancer cells to chemotherapeutic drugs by tyrosine kinase inhibitor emodin. Oncogene 1996;12:571-576.
26. Koyama J, Morita I, Tagahara K et al. Chemopreventive effects of emodin and cassiamin B in mouse skin carcinogenesis. Cancer Lett 2002;182:135-139.
27. Kuo P-L, Lin T-C, Lin C-C. The antiproliferative activity of aloe-emodin is through p53-dependent and p21-dependent apoptotic pathway in human hepatoma cell lines. Life Sci 2002;71:1879-1892.
28. Srinivas G, Anto RJ, Srinivas P et al. Emodin induces apoptosis of human cervical cancer cells through poly(ADP-ribose) polymerase cleavage and activation of caspase-9. Eur J Pharmacol 2003;473:117-125.

Citations and Reference Literature: Cascara

29. Shieh D-E, Chen Y-Y, Yen M-H et al. Emodin-induced apoptosis through p53-dependent pathway in human hepatoma cells. *Life Sci* 2004;74:2279-2290.
30. Castiglioni F, Tagliabue E, Campiglio M et al. Role of exon-16-deleted HER2 in breast carcinomas. *Endocr Relat Cancer* 2006;13:221-232.
31. Zhang L, Lau YK, Xia W et al. Tyrosine kinase inhibitor emodin suppresses growth of HER-2/neu-overexpressing breast cancer cells in athymic mice and sensitizes these cells to the inhibitory effect of paclitaxel. *Clin Cancer Res* 1999;5:343-353.
32. Wang SC, Zhang L, Hortobagyi GN, Hung MC. Targeting HER2: recent developments and future directions for breast cancer patients. *Semin Oncol* 2001;28:21-29.
33. Chen J-S, Lan K, Hung M-C. Strategies to target HER2/neu overexpression for cancer therapy. *Drug Resist Update* 2003;6:129-136.
34. Hamid O. Emerging treatments in oncology: focus on tyrosine kinase (erbB) receptor inhibitors. *J Am Pharm Assoc (Wash DC)* 2004;44:52-58.
35. Boik J. *Natural Compounds in Cancer Therapy*. Princeton, MN: Oregon Medical Press; 2001.
36. Bosch R, Friederich U, Lutz WK et al. Investigations on DNA binding in rat liver and in *Salmonella* and on mutagenicity in the Ames test by emodin, a natural anthraquinone. *Mutat Res* 1987;188:161-168.
37. Mengs U, Krumbiegel G, Volkner W. Lack of emodin genotoxicity in the mouse micronucleus assay. *Mutat Res* 1997;393:289-293.
38. Mueller SO, Lutz WK, Stopper H. Factors affecting the genotoxic potency ranking of natural anthraquinones in mammalian cell culture systems. *Mutat Res* 1998;414:125-129.
39. Brinker F. The Hoxsey treatment: cancer quackery or effective physiological adjuvant? *J Naturopath Med* 1996;6:9-23.
40. Neims DM, McNeill J, Giles TR, Todd F. Incidence of laxative abuse in community and bulimic populations: a descriptive review. *Int J Eat Disord* 1995;17:211-228.
41. Aitchison JD. Hypokalaemia following chronic diarrhea from overuse of cascara and a deficient diet. *Lancet* 1958;2:75-76.
42. Krahn LE, Lee J, Richardson JW et al. Hypokalemia leading to torsades de pointes. Munchausen's disorder or bulimia nervosa? *Gen Hosp Psychiatry* 1997;19:370-377.
43. Wang DJ, Chu KM, Chen JD et al. [Drug interaction between digoxin and bisacodyl]. *J Formos Med Assoc* 1990;89:915-919, 913.
44. Muller-Lissner S. [Side effects of laxatives]. *Z Gastroenterol* 1992;30:418-427.
45. Muller-Lissner SA. Adverse effects of laxatives: fact and fiction. *Pharmacology* 1993;47 Suppl 1:138-145.